Lung最新文献

{"title":"High-Density Lipoprotein Cholesterol Trajectories and Lung Function Decline: A Prospective Cohort Study.","authors":"Byunghun Yoo, Sun Ho Jung, Soo Han Bae, Young Sam Kim, Chanho Lee","doi":"10.1007/s00408-025-00809-3","DOIUrl":"10.1007/s00408-025-00809-3","url":null,"abstract":"<p><strong>Purpose: </strong>Cholesterol regulation is essential to maintain pulmonary homeostasis. Studies suggest that increased high-density lipoprotein cholesterol (HDL-C) levels correlate with better lung function. However, the longitudinal association of HDL-C with lung function remains unknown. We aimed to analyze the long-term correlation of HDL-C with lung function decline in a population-based cohort study.</p><p><strong>Methods: </strong>We included 7,652 participants from a prospective community-based cohort study in South Korea. Participants were categorized into five trajectory groups based on repeated HDL-C measurements. Generalized linear mixed models with random intercepts and slopes were used to examine the longitudinal relationship between HDL-C levels and lung function decline within these groups.</p><p><strong>Results: </strong>In the five HDL-C trajectory group analyses, the very low HDL-C trajectory group (Group 1) showed faster declines in forced vital capacity (FVC) (-3.1 mL/year) and forced expiratory volume in one second (FEV₁) (-3.1 mL/year) than the middle HDL-C group (Group 3, the reference group) did. The low HDL-C trajectory group (Group 2) also exhibited faster FVC (-1.5 mL/year) and FEV₁ (-1.7 mL/year) declines than the middle HDL-C group; however, the estimated difference was smaller than that in Group 1. Faster lung function decline in the low HDL-C trajectory group was consistently observed even when the population was analyzed using three- or four-HDL-C trajectory groups instead of five.</p><p><strong>Conclusion: </strong>Participants in the low HDL-C trajectory groups experienced a more rapid lung function decline over time than the reference groups, suggesting a negative longitudinal association between HDL-C and lung function decline.</p>","PeriodicalId":18163,"journal":{"name":"Lung","volume":"203 1","pages":"54"},"PeriodicalIF":4.6,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11950013/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143719988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Update 2025: Management of Non‑Small-Cell Lung Cancer.","authors":"Hyein Jeon, Shuai Wang, Junmin Song, Harjot Gill, Haiying Cheng","doi":"10.1007/s00408-025-00801-x","DOIUrl":"10.1007/s00408-025-00801-x","url":null,"abstract":"<p><p>Lung cancer remains the leading cause of cancer-related mortality worldwide. Since 2024, the non-small-cell lung cancer (NSCLC) landscape has undergone a transformative shift, driven by 11 FDA approvals. Recent advances in molecular profiling, targeted therapies, and immunotherapies have revolutionized NSCLC management, ushering in an era of personalized treatment with improved patient outcomes. The increased adoption of low-dose computed tomography (LDCT) for screening has enhanced early detection, enabling intervention at more curable stages. Molecular diagnostics now play a pivotal role in guiding treatment strategies, with actionable genomic alterations (AGAs) informing the use of EGFR, ALK, ROS1, KRAS, NRG1, and other targeted inhibitors in both early and advanced settings. For instance, targeted therapies are increasingly being integrated into early-stage management, with adjuvant osimertinib for EGFR-mutated NSCLC and alectinib for ALK-positive NSCLC demonstrating substantial survival benefits. Immunotherapy, particularly immune checkpoint inhibitors, has become a cornerstone of treatment for AGA-negative NSCLC, either as monotherapy or in combination with chemotherapy, and is increasingly being utilized in the perioperative setting. Furthermore, emerging therapies such as bispecific antibodies, antibody-drug conjugates (ADCs), and novel immunotherapeutic agents show promise in addressing resistance mechanisms and improving outcomes in advanced-stage disease. Although new challenges arise, the evolving NSCLC treatment paradigm continues to prioritize precision medicine, offering hope for prolonged survival and enhanced quality of life for patients.</p>","PeriodicalId":18163,"journal":{"name":"Lung","volume":"203 1","pages":"53"},"PeriodicalIF":4.6,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11937135/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143710546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dasatinib-Associated Chylothorax: A Review of Cases Reported to the FDA Adverse Event Reporting System and the Published Literature.","authors":"David A Kaland, Graça M Dores, Afrouz Nayernama, S Christopher Jones","doi":"10.1007/s00408-025-00804-8","DOIUrl":"https://doi.org/10.1007/s00408-025-00804-8","url":null,"abstract":"","PeriodicalId":18163,"journal":{"name":"Lung","volume":"203 1","pages":"52"},"PeriodicalIF":4.6,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143700914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship of Lung Function and the Preserved Ratio Impaired Spirometry Pattern with Aortic and Left Ventricular Structure and Function on Magnetic Resonance Imaging: The Jackson Heart Study.","authors":"Tasnim F Imran, Gaurav Choudhary, James G Terry, Yuan-I Min, Matthew Jankowich","doi":"10.1007/s00408-025-00808-4","DOIUrl":"10.1007/s00408-025-00808-4","url":null,"abstract":"<p><strong>Introduction: </strong>Low lung function and Preserved Ratio Impaired Spirometry (PRISm) have been associated with increased co-morbid cardiovascular disease. However, the association of abnormal lung function and PRISm with imaging markers of cardiovascular dysfunction has not been well elucidated.</p><p><strong>Methods: </strong>Participants from the Jackson Heart Study who had spirometry measurements at baseline and underwent cardiac magnetic resonance (CMR) were included. Multivariable adjusted associations between forced expiratory volume in the first second (FEV1) and forced vital capacity (FVC) and markers of aortic (pulse wave velocity, aPWV, wall thickness) and cardiac function (left ventricular (LV) stroke volume, and indexed LV mass) as measured on CMR were examined using linear regression models. Study participants were then divided into three groups (normal spirometry: FEV1/FVC ≥ 0.70, FEV1 ≥ 80%, airflow obstruction: FEV1/FVC < 0.70, and PRISm: FEV1/FVC ≥ 0.70, FEV1 < 80%). We then examined the associations of spirometry pattern and markers of structure and function as dichotomous outcomes using multivariable adjusted logistic regression models.</p><p><strong>Results: </strong>A total of 1278 participants (788 women [63%]; 375 (29%) ever smokers, 612 (48%) with hypertension, 1033 [81%] with normal spirometry, 80 [6%] with airflow obstruction, and 165 (13%) with PRISm met criteria for inclusion. In a multivariable model adjusting for age, sex, BMI, smoking status, and systolic blood pressure, aPWV was significantly associated with FEV1% (-0.20 ± 0.03, p = 0.04) and those with airflow obstruction had significantly higher odds of an increased aPWV (OR 2.25, 95% CI 1.29-3.93) compared to controls with a normal spirometry pattern. In the multivariable adjusted model, those with PRISm had a higher likelihood of a reduced LV stroke volume compared to controls (OR 1.69, 95% CI 1.14-2.56).</p><p><strong>Discussion: </strong>The PRISm pattern is associated with decreased LV stroke volume. This may be a potential mechanism between PRISm pattern and incident heart failure.</p>","PeriodicalId":18163,"journal":{"name":"Lung","volume":"203 1","pages":"51"},"PeriodicalIF":4.6,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143670384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma Reticulocalbin 3 (RCN3) is a Novel Biomarker for the Early Diagnosis of Hepatopulmonary Syndrome in Cirrhotic Patients.","authors":"Fangping Ding, Liu Yang, Wenhui Cao, Jie Sun, Fengwei Shi, Yingfei Wang, Caixia Hu, Weiwei Kang, Jing Han, Qingkun Song, Yingmin Ma, Jiawei Jin","doi":"10.1007/s00408-025-00807-5","DOIUrl":"10.1007/s00408-025-00807-5","url":null,"abstract":"<p><strong>Background: </strong>Hepatopulmonary syndrome (HPS) is a severe complication in cirrhotic patients and characterized by abnormal intrapulmonary vasodilation (IPVD), resulting in impaired oxygenation. Recent studies highlight the pivotal role and clinical merit of Reticulocalbin 3 (RCN3) in interstitial pulmonary remodeling.</p><p><strong>Objectives: </strong>This study aimed to investigate the clinical value of plasma RCN3 for early diagnosis of HPS in cirrhotic patients.</p><p><strong>Methods: </strong>This prospective observational study on a cohort including 41 healthy control subjects and 247 cirrhotic patients with/without HPS, in which most HPS occurs in the mild stage. Plasma levels of RCN3 and key HPS-associated vasoactive factors are compared between patients with and without HPS/IPVD. The predictive value of RCN3 for the diagnosis of HPS is further analyzed.</p><p><strong>Results: </strong>Patients with HPS had a severe condition. Plasma RCN3 was decreased in cirrhotic patients versus health control, but it is significantly higher in patients with HPS/IPVD than without non-HPS/IPVD. Notably, RCN3 level is positively correlated with P(A-a)O₂ and MELD scores as well as plasma levels of angiogenetic factors VEGF and AngII. Although the plasma levels of vasoactive factors were significantly different between HPS and non-HPS patients, only plasma RCN3 and albumin are independently associated with HPS in cirrhotic patients. Plasma RCN3 exhibits better predictive value in HPS diagnosis (RCN3, AUC = 0.657, 95% CI 0.571-0.744, p < 0.001). Interestingly, the combination of RCN3 and albumin achieves more efficiency in HPS prediction (AUC = 0.711, 95% CI 0.630-0.792, p < 0.0001).</p><p><strong>Conclusions: </strong>Circulating RCN3 is likely a relatively specific earlier biomarker for the prediction of early or latent HPS in cirrhotic patients, and the combination of RCN3-ALB can achieve more efficiency in HPS prediction.</p>","PeriodicalId":18163,"journal":{"name":"Lung","volume":"203 1","pages":"50"},"PeriodicalIF":4.6,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143670383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Efficacy of CFTR Modulators: A Network Meta-analysis.","authors":"Imran Hasan Iftikhar, Saad T Rao, Rufai Nadama, Ibrahim Janahi, Ahmed S BaHammam","doi":"10.1007/s00408-025-00802-w","DOIUrl":"10.1007/s00408-025-00802-w","url":null,"abstract":"<p><strong>Purpose: </strong>The objective was to study comparative efficacies of cystic fibrosis transmembrane conductance regulator (CFTR) modulators, vanzacaftor-tezacaftor-deutivacaftor (VTD), elexacaftor-tezacaftor-ivacaftor (ETI), tezacaftor-ivacaftor (Tez-Iva), and lumacaftor-ivacaftor (Lum-Iva) in people with cystic fibrosis (pwCF), aged ≥ 12 years, carrying at least one F508del-CFTR-allele.</p><p><strong>Methods: </strong>Data from randomized controlled or randomized active comparator trials were included in this network meta-analysis which used frequentist approach for comparing the efficacy of drugs and ranking based on P-scores. Outcomes of interest were mean differences in percentage-predicted forced expiratory volume in one second (ppFEV₁), CF questionnaire-revised respiratory domain (CFQ-R) scores, sweat chloride (SwCl) levels, and odds ratios (OR) for serious adverse events (SAE).</p><p><strong>Results: </strong>Data from 13 studies were analyzed. Compared to placebo, the effects of VTD and ETI on ppFEV1 were almost quadruple of Tez-Iva and Lum-Iva (VTD: 12.78 [95% confidence intervals: 6.41; 19.15] and ETI: 11.95 [7.40; 16.50]) and almost seven times of Tez-Iva and Lum-Iva for CFQ-R (VTD: 21.23 [- 28.72; 71.18] and ETI: 19.27 [10.56; 27.98]). A statistically significant difference was noted between VTD and ETI in SwCl reduction (mean difference: - 8.59 [- 15.53; - 1.65]). There were no statistically significant ORs for SAEs for any CFTR modulators but VTD, ETI, and Tez-Iva were least associated with SAEs (ORs were 0.15 [0.01; 1.79], 0.49 [0.31; 0.78], and 0.74 [0.50; 1.09], respectively, as compared to placebo). Overall, P-score ranking ranked VTD as first and ETI as second, followed by others.</p><p><strong>Conclusion: </strong>VTD and ETI were more efficacious than Tez-Iva and Lum-Iva in pwCF with at least one F508del-CFTR-allele.</p>","PeriodicalId":18163,"journal":{"name":"Lung","volume":"203 1","pages":"49"},"PeriodicalIF":4.6,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143657656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Electronic Cigarette Vapour Exposure on Ca²⁺- and cAMP-Dependent Ion Transport in Human Airway Epithelial Cells.","authors":"Ya Niu, Chung-Yin Yip, Ke-Wu Pan, Judith Choi-Wo Mak, Wing-Hung Ko","doi":"10.1007/s00408-025-00805-7","DOIUrl":"10.1007/s00408-025-00805-7","url":null,"abstract":"<p><strong>Purpose: </strong>The popularity of electronic cigarettes (e-cigarettes) has grown exponentially over the past few years, and teenagers now prefer them to tobacco cigarettes. We determined whether exposure to e-cigarette vapour (e-vapour) adversely affects ion transport using human airway epithelial cell lines 16HBE14o- and Calu-3 and well-differentiated primary human bronchial epithelial cells (HBEs).</p><p><strong>Methods: </strong>We concurrently measured fluorescent signals and short-circuit current (I_SC), an indicator of electrogenic ion transport, in polarised epithelia. The P2Y receptor-mediated signalling pathway was used to induce an increase in intracellular calcium concentration ([Ca²⁺]_i) and I_SC. We used a single-polypeptide fluorescence resonance energy transfer reporter based on exchange proteins directly activated by cAMP (Epac) to measure forskolin-induced changes in cAMP and I_SC.</p><p><strong>Results: </strong>We compared the effects of e-vapour to those of traditional cigarette smoke (CS) on the human airway cell models. In all three cell types, e-vapour, similar to CS, significantly reduced agonist-induced increases in Ca²⁺ or cAMP signalling and I_SC. However, reductions in the epithelial electrolyte transport activities did not correlate with any changes in the protein levels of various ion channels and transporters.</p><p><strong>Conclusion: </strong>Our data suggest that e-vapour is not harmless and causes ion transport dysfunction similar to CS, thereby predisposing e-cigarette users to vaping-induced lung injury.</p>","PeriodicalId":18163,"journal":{"name":"Lung","volume":"203 1","pages":"48"},"PeriodicalIF":4.6,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11920333/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143657666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of HDAC3 in Pulmonary Diseases.","authors":"Leyu Hong, Ming Ni, Fei Xue, Tao Jiang, Xuanpeng Wu, Chenxi Li, Shuhao Liang, Tianhao Chen, Chao Luo, Qifei Wu","doi":"10.1007/s00408-025-00798-3","DOIUrl":"10.1007/s00408-025-00798-3","url":null,"abstract":"<p><p>Histone deacetylases (HDACs), a class of enzymes involved in epigenetic modifications, play a pivotal role in modulating chromatin structure and gene expression. Among these, histone deacetylase 3 (HDAC3) has emerged as a key regulator in diverse cellular pathophysiological processes. The remarkable therapeutic potential of HDAC inhibitors in lung cancer has intensified research into the role of HDAC3 in pulmonary diseases. Through deacetylating histones and non-histone proteins, HDAC3 has been increasingly recognized for its critical involvement in regulating inflammatory responses, fibrotic processes, and oncogenic signaling pathways, positioning it as a compelling therapeutic target. This review systematically examines the structural and functional features of HDAC3 and discusses its multifaceted contributions to pulmonary pathologies, including lung injury, pulmonary fibrosis, and lung cancer. Additionally, we critically evaluate advances in HDAC inhibitor-based therapies for lung cancer, with emphasis on the development of HDAC3-targeted therapies. As a promising therapeutic target for pulmonary diseases, HDAC3 needs to be further investigated to elucidate its regulatory mechanisms and facilitate the development of selective inhibitors for clinical translation.</p>","PeriodicalId":18163,"journal":{"name":"Lung","volume":"203 1","pages":"47"},"PeriodicalIF":4.6,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143649695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors Influencing the Efficacy and Safety of Monoclonal Antibody Biologics in Chronic Obstructive Pulmonary Disease: A Meta-analysis of Randomized Controlled Trials.","authors":"Yuxin Wang, Jinmei Luo, Rong Huang, Yi Xiao","doi":"10.1007/s00408-025-00795-6","DOIUrl":"https://doi.org/10.1007/s00408-025-00795-6","url":null,"abstract":"<p><strong>Background: </strong>Monoclonal antibody therapies targeting specific inflammatory pathways have shown potential in treating chronic obstructive pulmonary disease (COPD). However, the efficacy and safety of these treatments across different patient phenotypes remain uncertain.</p><p><strong>Methods: </strong>This meta-analysis included 15 registered randomized controlled trials (RCTs) evaluating monoclonal antibodies targeting type 2 and non-type 2 inflammatory pathways in COPD. The primary outcomes assessed were rates of moderate to severe exacerbations, rates of severe exacerbations, lung function (pre- and post-bronchodilator FEV₁), St. George's Respiratory Questionnaire (SGRQ) scores, and safety-related events. Subgroup analyses were performed based on inflammatory phenotype, exacerbation frequency, and smoking status. Meta-regression was used to examine the influence of covariates, such as baseline FEV₁%pred and other demographic factors.</p><p><strong>Results: </strong>Monoclonal antibody therapies significantly reduced the rates of moderate to severe exacerbations (RR 0.88, 95% CI 0.83-0.93) and severe exacerbations (RR 0.82, 95% CI 0.72-0.94). Subgroup analyses revealed more pronounced benefits in eosinophilic and frequent exacerbator phenotypes. Non-eosinophilic patients demonstrated a better response to IL-33-targeting therapies. Lung function and quality of life showed modest improvements across most therapies. Smoking status and baseline FEV₁ were significant modifiers of treatment efficacy. No significant increase in serious adverse events was noted.</p><p><strong>Conclusions: </strong>Monoclonal antibody therapies, particularly those targeting type 2 inflammation, effectively reduce exacerbation rates in COPD, with greater benefits observed in patients with eosinophilic phenotypes and frequent exacerbations. Baseline lung function also influences treatment response. These findings underscore the importance of personalized, phenotype-driven treatment approaches and support the continued development of biologics for COPD management.</p>","PeriodicalId":18163,"journal":{"name":"Lung","volume":"203 1","pages":"46"},"PeriodicalIF":4.6,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MIP-3-Alpha and MIP-3-Beta as Early Predictors of Pneumonia in Polytraumatized Patients.","authors":"Gregor Wollner, Florian Hruska, Paul Ettel, Thomas Weichhart, Felix R M Koenig, Lukas L Negrin","doi":"10.1007/s00408-025-00799-2","DOIUrl":"10.1007/s00408-025-00799-2","url":null,"abstract":"<p><strong>Introduction: </strong>Pneumonia is one of the most common complications in patients suffering multiple traumas and is associated with an exceptionally high mortality rate. MIP-3-alpha and MIP-3-beta are pro-inflammatory chemokines expressed in the pulmonary mucosa and are reported to play a crucial role in inflammation. Thus, the present study aimed to investigate whether there is an association between MIP-3-alpha- and MIP-3-beta expression and manifestation of pneumonia in patients suffering polytrauma.</p><p><strong>Material and methods: </strong>This prospective outcome study was conducted at our level I trauma center, and 110 polytraumatized patients (Injury Severity Score ≥ 16, ≥ 2 body regions) were prospectively enrolled (median age, 39 years; median Injury Severity Score (ISS), 33; 70.9% male) over four years. Protein levels were assessed at admission (day 0) and subsequently on days 1, 3, 5, 7, and 10 during routine blood draws, utilizing one separation gel tube for each measurement. Furthermore, the correlation between MIP-3-alpha- and MIP-3-beta expression and the manifestation of pneumonia was calculated.</p><p><strong>Results: </strong>We observed significantly higher levels of MIP-3-beta expression over the entire time course in the pneumonia cohort. MIP-3-alpha levels were elevated on days 3, 5, 7, and 10 post-trauma in patients suffering from pneumonia. In contrast, no comparable pattern was observed for other pro- and anti-inflammatory cytokines (e.g., IL-6 or TNF-alpha). A peak of serum level expression was documented on day 5 in both biomarkers (MIP-3-alpha 51.8 pg/mL; MIP-3-beta 328.0 pg/mL). ROC analysis provided a cut-off value of 19.3 pg/mL (sensitivity 0.87, specificity 0.33; AUC 0.757) for MIP-3-alpha, whereas a cut-off value of 209.5 pg/mL (sensitivity 0.78, specificity 0.34; AUC 0.757) was determined for MIP-3-beta on day 5.</p><p><strong>Conclusion: </strong>The present study demonstrated elevated MIP-3-alpha and MIP-3-beta levels as sensitive pneumonia predictors in patients with multiple traumas. These biomarkers allow for identifying patients at high risk of developing pneumonia at an early stage.</p>","PeriodicalId":18163,"journal":{"name":"Lung","volume":"203 1","pages":"44"},"PeriodicalIF":4.6,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11903586/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143615826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}